Key clinical point: Adding pertuzumab to first-line trastuzumab and docetaxel improves long-term outcomes in patients with metastatic HER2-positive breast cancer.
Major finding: With a median follow-up of 99.9 months, the median overall survival was 57.1 months in the pertuzumab arm and 40.8 months in the placebo arm (hazard ratio, 0.69; 95% CI, 0.58-0.82).
Study details: End-of-study analysis of a phase 3 randomized trial of first-line therapy in 808 patients with metastatic HER2-positive breast cancer.
Disclosures: F. Hoffmann-La Roche and Genentech funded the trial. The authors disclosed relationships with these and other companies.
Swain SM et al. Lancet Oncol. 2020 Mar 12. doi: 10.1016/S1470-2045(19)30863-0.